Inventor · disambiguated record
Art Taveras
Also filed as: TAVERAS ART
6 granted patents·8 pending applications·60 citations·filing 2010–2023
84Inventor score
Files withBIOGEN MA INC3X4 PHARMACEUTICALS INC3BUI MINNA2SUNESIS PHARMACEUTICALS INC2VIRACTA THERAPEUTICS INC2
Top patents by PatentIndex Score
14 records- 0192US9790229B2Bruton's tyrosine kinase inhibitorsBIOGEN MA INC·Filed 2016·Granted Oct 17, 2017·11 cites·21 claims
- 0291US8785440B2Bruton's tyrosine kinase inhibitorsBUI MINNA·Filed 2010·Granted Jul 22, 2014·20 cites·20 claims
- 0389US9249146B2Bruton'S tyrosine kinase inhibitorsBIOGEN IDEC INC·Filed 2014·Granted Feb 2, 2016·9 cites·25 claims
- 0484US9029359B2Heteroaryl Btk inhibitorsBUI MINNA·Filed 2010·Granted May 12, 2015·12 cites·18 claims
- 0584US2024246988A1Bruton's tyrosine kinase inhibitorsVIRACTA THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0683US9273028B2Heterocyclic tyrosine kinase inhibitorsHOPKINS BRIAN T·Filed 2011·Granted Mar 1, 2016·6 cites·8 claims
- 0782US10577374B2Bruton's tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2017·Granted Mar 3, 2020·2 cites·18 claims
- 0878US2023046457A1Bruton's tyrosine kinase inhibitorsVIRACTA THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 0970US2020399283A1Bruton's tyrosine kinase inhibitorsSUNESIS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1060US2025361307A1Combination therapies for treating hyperproliferative disordersX4 PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1158US2025041292A1Methods for treating primary immunodeficiencyX4 PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1256US2025326753A1Dual cxcr4-btk inhibitorsX4 PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1352US2016039825A1S1p and/or atx modulating agentsBIOGEN MA INC·Filed 2014·Application pending·0 cites
- 1450US2017027956A1Heterocyclic tyrosine kinase inhibitorsBIOGEN MA INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Art Taveras files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →